CompanyIntelligence | Cima Labs Inc.

The Consus Group provides critical intelligence for the
business, investor, and legal communities.

Documents can be downloaded immediately after purchase. Complete your order by clicking the Add-to-Cart button.

$39	Subscribers	2003	aaiPharma and Cima Announce Merger to Create a Leading Science-Based, Specialty Pharmaceutical Company	aaiPharma; Cima Labs	Faegre & Benson; Latham & Watkins
$32	Subscribers Preview	2004	Agreement to File Joint Acquisition Statements	Cima Labs Inc.
$36	Subscribers Preview	2004	Cephalon, Inc. and Cima Labs Inc. Announce Agreement in Principle with FTC Staff on Proposed Merger	Cephalon, Inc.	Cima Labs Inc.
$33	Subscribers Preview	2004	Cephalon, Inc. and Cima Labs Inc. Announce FTC Clearance to Proceed with Merger	Cephalon, Inc.	Cima Labs Inc.
$33	Subscribers Preview	2004	Cephalon, Inc. and CIMA Labs Inc. Announce FTC Clearance to Proceed with Merger	James Hawley; Robert Grupp; Chip Merritt	Cephalon; Cima Labs
$32	Subscribers Preview	2004	Cephalon, Inc. and Cima Labs Inc. Receive FTC Request for Additional Information	Chip Merritt; Robert Grupp; James Hawley	Cephalon; Cima Labs
$38	Subscribers Preview	2003	Cephalon, Inc. and CIMA Labs Inc. Sign Definitive Merger Agreement	James Hawley; Chip Merritt; aaiPharma	Cephalon; Cima Labs; Deutsche Bank
$33	Subscribers	2003	Cephalon, Inc. and Cima Labs Inc. Sign Definitive Merger Agreement	aaiPharma; Cephalon	Cima Labs; Deutsche Bank
$43	Subscribers Preview	2004	Cephalon, Inc. Reports First Quarter Financial Results	Cephalon, Inc.	Cima Labs Inc.
$32	Subscribers Preview	2004	Cephalon, Inc. Reports Record Financial Results for 2003	Cephalon, Inc.	Cima Labs Inc.
$36	Subscribers	2004	Cima Labs Announces First-Quarter Financial Results; Patient Enrollment Begins in Oravescent Fentanyl Phase III Clinical Trials	Cephalon; Cima Labs	Wyeth
$38	Subscribers	2004	Cima Labs Announces Fourth-Quarter and Full-Year 2003 Financial Results; Company Reports Seventh Consecutive Quarter of Record Revenues	aaiPharma; Cephalon	Cima Labs
$43	Subscribers Preview	2003	Cima Labs Announces Record Results For First Quarter of 2003 Revenues Nearly Double, Operating Income Rises More Than 150% Year-Over-Year	Cima Labs Inc.	Wyeth
$42	Subscribers Preview	2000	Cima Labs Announces Record Third Quarter Results	Cima Labs Inc.
$36	Subscribers	2003	Cima Labs Announces Second-Quarter 2003 Financial Results	Cima Labs Inc.
$39	Subscribers	2003	Cima Labs Announces Third-Quarter 2003 Financial Results; Product Sales More Than Double, Royalties Up 76 Percent Year-Over-Year	aaiPharma Inc.	Cima Labs Inc.
$36	Subscribers	2003	Cima Labs Receives Letter from Cephalon, Inc. Regarding Earlier Proposal	Cephalon, Inc.	Cima Labs Inc.
$32	Subscribers	2003	Cima Labs Receives Letter Proposing Business Combination	aaiPharma Inc.	Cima Labs Inc.
$37	Subscribers	2003	Cima Labs Receives Proposal from Cephalon, Inc. for Alternative Transaction	aaiPharma; Cephalon	Cima Labs
$41	Subscribers	2003	Cima Labs Responds to Cephalons Unsolicited Acquisition Proposal	aaiPharma; Cephalon	Cima Labs